Osaic Holdings
RPRX icon

Osaic Holdings’s Royalty Pharma RPRX Stock Holding History

Osaic Holdings’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Buy
19,681
+5,692
+41% +$296K ﹤0.01% 2911
2026
Q1 		$671K Sell
13,989
-26,641
-66% -$1.17M ﹤0.01% 3080
2025
Q4 		$1.57M Sell
40,630
-99,612
-71% -$3.8M ﹤0.01% 2293
2025
Q3 		$4.95M Buy
140,242
+133,138
+1,874% +$4.82M 0.01% 1477
2025
Q2 		$254K Buy
7,104
+4,078
+135% +$135K ﹤0.01% 3738
2025
Q1 		$94.2K Sell
3,026
-3,805
-56% -$121K ﹤0.01% 4220
2024
Q4 		$105K Buy
6,831
+2,240
+49% +$59.4K ﹤0.01% 4136
2024
Q3 		$130K Buy
4,591
+133
+3% +$3.68K ﹤0.01% 4017
2024
Q2 		$118K Buy
4,458
+560
+14% +$15.5K ﹤0.01% 4005
2024
Q1 		$118K Buy
3,898
+425
+12% +$12.5K ﹤0.01% 4123
2023
Q4 		$97.6K Sell
3,473
-1,289
-27% -$35.4K ﹤0.01% 4460
2023
Q3 		$129K Sell
4,762
-257
-5% -$7.63K ﹤0.01% 4308
2023
Q2 		$154K Sell
5,019
-64
-1% -$2.17K ﹤0.01% 4104
2023
Q1 		$183K Buy
5,083
+904
+22% +$33.5K ﹤0.01% 3935
2022
Q4 		$165K Sell
4,179
-165
-4% -$6.89K ﹤0.01% 4023
2022
Q3 		$175K Sell
4,344
-298
-6% -$12.7K ﹤0.01% 3877
2022
Q2 		$195K Buy
4,642
+377
+9% +$15.5K ﹤0.01% 3821
2022
Q1 		$151K Buy
4,265
+366
+9% +$14.4K ﹤0.01% 4258
2021
Q4 		$155K Buy
3,899
+716
+22% +$27.8K ﹤0.01% 4196
2021
Q3 		$115K Sell
3,183
-3,678
-54% -$143K ﹤0.01% 4410
2021
Q2 		$281K Sell
6,861
-8,005
-54% -$341K ﹤0.01% 3578
2021
Q1 		$648K Sell
14,866
-1,855
-11% -$87.9K ﹤0.01% 2611
2020
Q4 		$837K Sell
16,721
-1,221
-7% -$51.8K ﹤0.01% 2198
2020
Q3 		$754K Buy
17,942
+13,056
+267% +$560K ﹤0.01% 2061
2020
Q2 		$238K Buy
+4,886
New +$242K ﹤0.01% 2965

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings's RPRX Position: Q2 2026 in Review

Osaic Holdings increased its Royalty Pharma (RPRX) stake by 41% in Q2 2026, buying an estimated $296K and bringing the position to 19,681 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

Osaic Holdings first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. The position peaked at $4.95M in Q3 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Osaic Holdings held 19,681 shares of Royalty Pharma worth $1.1M as of Q2 2026.
  • Osaic Holdings bought 5,692 Royalty Pharma shares in Q2 2026, an estimated $296K.
  • Royalty Pharma made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #2911 holding.
  • Osaic Holdings first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • Osaic Holdings's Royalty Pharma position peaked at $4.95M in Q3 2025.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.